Single-Pill Combination of Perindopril/Indapamide/Amlodipine in Patients with Uncontrolled Hypertension: A Randomized Controlled Trial

Cardiology and Therapy

Volumn 6, Issue 1, 2017, Pages 91-104

  Nedogoda, Sergey V ^a   Stojanov, Vesna J ^b  

^a VOLGOGRAD STATE MEDICAL UNIVERSITY   (Russian Federation)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Amlodipine; Antihypertensive; Indapamide; Perindopril; Single pill combination; Uncontrolled essential hypertension

Indexed keywords

AMLODIPINE; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; CREATININE; INDAPAMIDE; PERINDOPRIL; POTASSIUM; URIC ACID;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SMOKING; TREATMENT DURATION; URINALYSIS;

EID: 85034959061     PISSN: 21938261     EISSN: 21936544     Source Type: Journal    
DOI: 10.1007/s40119-017-0085-7     Document Type: Article

References (51)

1. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. Guidelines for the Management of Arterial Hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.
2. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.
3. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3–15.
4. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. Clinical Guidelines CG127. 2011.
5. Benoit G, Feber J, Harris KD, Poirier L, Padwal RS, For the Canadian Hypertension Education Program. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2015;31:549–68.
6. Tykarski A, Narkiewicz K, Gaciong Z, Polish Society of Hypertension, et al. 2015 guidelines for the management of hypertension. Recommendations of the Polish Society of Hypertension. Arterial Hypertens. 2015;19:53–83.
7. Mancia G, De Backer G, Dominiczak A, The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462–1536.
8. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy vs. monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290–300.
9. Leung AA, Nerenberg K, Daskalopoulou SS, CHEP Guidelines Task Force, et al. Hypertension Canada’s 2016 Canadian Hypertension Education Program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016;32:569–88.
10. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010;12:869–78.
11. Elijovich F, Laffer C. A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis. 2009;3:231–40.
12. Black HR. Triple fixed-dose combination therapy. Back to the past. Hypertension. 2009;54:19–22.
13. Neutel JM, Smith DH. Hypertension management: rationale for triple therapy based on mechanisms of action. Cardiovasc Ther. 2013;31:251–8.
14. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011;124:128–35.
15. Chung N, Baek S, Chen MF, et al. Expert recommendations on the challenges of hypertension in Asia. Int J Clin Pract. 2008;62:1306–12.
16. Remme WJ, McMurray JJ, Hobbs FD, et al. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J. 2008;29:1739–52.
17. Liu L. 2010 Chinese guidelines for the management of hypertension. Chin J Cardiol. 2011;39:579–616.
18. Sociedade Brasileira de Cardiologia (SBC). 7a Diretriz Brasileira de Hipertensão Arterial. Arq Bras Cardiol. 2016;107(3 Suppl.3):1–83.
19. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J. 2016;. doi:10.1093/eurheartj/ehw106.
20. Russian Society on Hypertension. All-Russian Scientific Society of Cardiologists (VNOK). Diagnosis and treatment of arterial hypertension. Systemnye Hypertensii. 2010;3:5–26.
21. Fogari R, Zoppi A, Tettamanti F, Malamani GD, Tinelli C, Salvetti A. Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors: a double-blind, randomized, cross-over study. J Cardiovasc Pharmacol. 1992;19:670–3.
22. Tóth K, Investigators PIANIST. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14:137–45.
23. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–41.
24. ADVANCE Collaborative Group. Effect of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet. 2007;370:829–40.
25. Beckett N, Peters R, Fletcher AE, For the HYVET Study Group, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.
26. Dahlof B, Sever P, Poulter N, For the ASCOT investigators, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–90.
27. Julius S, Kjeldsen SE, Weber M, VALUE trial group, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31.
28. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.
29. Jamerson K, Bakris GL, Dahlöf B, ACCOMPLISH Investigators, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16:80–6.
30. Chalmers J, Arima H, Woodward M, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes And Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014;63:259–64.
31. de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens. 2009;23:503–11.
32. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32:1252–69.
33. Calhoun DA, Crikelair NA, Yen J, Glazer RD. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: secondary analyses evaluating efficacy and safety. Adv Ther. 2009;26:1012–23.
34. Chen P, Chaugai S, Zhao F, Wang DW. Cardioprotective effect of thiazide-like diuretics: a meta-analysis. Am J Hypertens. 2015;28:1453–63.
35. Kaplan N. Treatment of hypertension: drug therapy—diuretics. In: Kaplan NM, editor. Clinical hypertension, 8th ed. Philadelphia, USA: Lippincott Williams and Wilkins; 2002. p. 241–252.
36. Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring. A meta-analysis of randomized trials. J Am Coll Cardiol. 2011;57:590–600.
37. NICE—Clinical Guidelines Hypertension: the clinical management of primary hypertension in adults—NCGC (National Clinical Guideline Centre) 127. 2011.
38. Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone antihypertensive and metabolic effects. Hypertension. 2015;65:1041–6.
39. Ferrari R, Rosano GM. Not just numbers, but years of science: putting the ACE inhibitor—ARB meta-analyses into context. Int J Cardiol. 2013;166:286–8.
40. Van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone-system inhibitors involving 158,998 patients. Eur Heart J. 2012;33:2088–97.
41. Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013;61:131–42.
42. Strauss MH, Hallb AS. The divergent cardiovascular effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on myocardial infarction and death. Prog Cardiovasc Dis. 2016;58:473–82.
43. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399–407.
44. Dragomir A, Cote R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48:418–25.
45. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713–9.
46. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239–45.
47. Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil. 2005;12:243–9.
48. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598–605.
49. Heisler M, Hogan MM, Hofer TP, Schmittdiel JA, Pladevall M, Kerr EA. When more is not better: treatment intensification among hypertensive patients with poor medication adherence. Circulation. 2008;117:2884–92.
50. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47:345–51.
51. Basile J, Neutel J. Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy. Ther Adv Cardiovasc Dis. 2010;4:119–27.